Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
DiaSorin has received FDA clearance for its Liaison aldosterone immunoassay, which is intended for the quantitative determination of aldosterone in human serum, EDTA plasma, and urine samples. The test is used primarily for the diagnosis of hypertension.
Applied Spectral Imaging and WaveSense have entered into an agreement in which both companies will engage in combined sales and marketing of ASI’s GenASIs imaging and analysis instrument and WaveSense’s EpiSep cell recovery and enrichment solution. The combined solution provides an integrated cell capturing solution and computerized instrument to detect, image, and analyze the captured cells.
Abbott announced CE Marking for its Architect clinical chemistry hemoglobin A1c (HbA1c) test, which may aid physicians in diagnosing and monitoring diabetes as well as identifying patients at risk for developing diabetes.
Crescendo Bioscience announced that the Wadsworth Center at the New York Department of Health, through its Clinical Laboratory Evaluation Program, issued a laboratory permit to Crescendo Bioscience to provide services to physicians in New York. Crescendo offers Vectra DA, a multi-biomarker blood test that measures disease activity in rheumatoid arthritis by integrating 12 key proteins consistently associated with the biology of RA into one objective, quantitative score to help physicians make more informed patient management decisions. Vectra DA is now
Audit MicroControls has added to its line of calibration verification/linearity products, the beta-hydroxybutyric acid linearity, five levels. The control is intended to simulate human patient serum samples for determining linearity, calibration verification, and verification of reportable range for beta-hydroxybutyric acid. Packaged as 5 × 1 mL, this liquid product has a shelf life of two years and an open-vial stability of seven days when stored at 2° to 8°C. Audit MicroControls, 866-252-8348
The FDA has approved Roche Diagnostics’ Tarceva (erlotinib) tablets for the initial treatment of people with metastatic non-small cell lung cancer (NSCLC) whose tumors have certain epidermal growth factor receptor (EGFR)-activating mutations as detected by an FDA-approved test. The FDA also approved Roche’s Cobas EGFR mutation test. In the United States, Tarceva is already approved, irrespective of histology or biomarker status, for people with advanced-stage NSCLC whose cancer has not spread or grown after initial treatment with certain types of
Boulder Diagnostics has launched in Europe its ParaFlor kits for the detection of Giardia, Cryptosporidium, and Blastocystis infections for human and veterinary applications. The rapid assays enable detection in less than 10 minutes in fresh and fixed stool samples. They are also available for veterinary applications and research use only in humans in the United States. The ParaFlor B kit is the first specific assay for the detection of the Blastocystis parasite. Boulder Diagnostics, 720-897-6276
ScopeLED, a division of Dicon Fiberoptics, has released its LED-based fluorescence microscope illuminator, which is designed to fit most clinical fluorescence microscopes. The ScopeLED F-series illuminators mount directly to the microscope’s fluorescence illuminator and look like a standard microscope lamp house. With more than 30,000 hours of LED lifetime, no maintenance should be required for over 12 to 15 years of heavy lab usage. Power consumption is under 5 W per hour compared to more than 300 W per hour
Siemens Healthcare Diagnostics has obtained FDA clearance for its anti-cyclic citrullinated peptide (anti-CCP) IgG assay to aid diagnosis of rheumatoid arthritis (RA). Available on the company’s Immulite 2000/2000 XPi immunoassay systems, the assay enables laboratories to integrate RA testing onto an automated, random-access analyzer. With a clinical specificity of 97 percent, the Immulite anti-CCP IgG assay is a highly accurate diagnostic tool for fast and early RA diagnosis. The assay helps rule out other inflammatory and arthritic conditions, enabling physicians
TriLink BioTechnologies has signed a licensing agreement with QuantiBact to offer twisted intercalating nucleic acid (TINA) modified oligonucleotides. TINA molecules are intercalators placed at the 5’ end of primers to stabilize duplex formation. Their properties improve the sensitivity and specificity of endpoint and real-time PCR. TINA oligos may find applications wherever an enhanced Tm is required, such as triplex formation or gene silencing. TINA-modified oligonucleotides are now available from TriLink. Visit trilink biotech.com/TINA for up-to-date information. TriLink BioTechnologies, 800-863-6801
